The major circulating metabolite of ketamine (norketamine) shown action at the same receptor with much less affinity. Norketamine is about one/3 as active as ketamine in reducing halothane prerequisites (MAC) with the rat. A form of ketamine called esketamine nasal spray was accepted from the FDA in 2019 underneath the https://ketalinic.com/